iData Insights

Bone Marrow Transplantation - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 22, 2016 17:22 IST

Bone Marrow Transplantation - Pipeline Review, H2 2015 Summary Global Markets Direct s, Bone Marrow Transplantation - Pipeline Review, H2 2015, provides an overview of the Bone Marrow Transplantations therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Marrow Transplantation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bone Marrow Transplantation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 7

Global Markets Direct Report Coverage 7

Bone Marrow Transplantation Overview 8

Therapeutics Development 9

Pipeline Products for Bone Marrow Transplantation - Overview 9

Pipeline Products for Bone Marrow Transplantation - Comparative Analysis 10

Bone Marrow Transplantation - Therapeutics under Development by Companies 11

Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes 12

Bone Marrow Transplantation - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Bone Marrow Transplantation - Products under Development by Companies 16

Bone Marrow Transplantation - Products under Investigation by Universities/Institutes 17

Bone Marrow Transplantation - Companies Involved in Therapeutics Development 18

Anchor Therapeutics, Inc. 18

Boryung Pharmaceutical Co., Ltd. 19

Cleveland BioLabs, Inc. 20

Compugen Ltd. 21

Mesoblast Limited 22

Pluristem Therapeutics Inc. 23

Proteonomix, Inc. 24

Taiga Biotechnologies, Inc. 25

Targazyme, Inc. 26

Bone Marrow Transplantation - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

(filgrastim + plerixafor) - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

ATI-2341 - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

BR-05001 - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

CBLB-612 - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Cell Therapy for Bone Marrow Transplantation - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

CGEN-15001 - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

MPC-CBE - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

PLXR-18 - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Protein for Bone Marrow Transplantation - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

TZ-101 - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Bone Marrow Transplantation - Recent Pipeline Updates 55

Bone Marrow Transplantation - Dormant Projects 65

Bone Marrow Transplantation - Discontinued Products 66

Bone Marrow Transplantation - Product Development Milestones 67

Featured News & Press Releases 67

Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematologys Annual Meeting 67

May 06, 2015: Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow 67

Mar 24, 2015: Pluristem Announces Key Strategic Objectives for Development of PLX-R18 in Hematopoietic Indications 68

Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation 68

Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes 70

Nov 13, 2014: Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials 70

Oct 27, 2014: Case Western Reserve University to Study Pluristems PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases 71

May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 72

Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use 72

May 09, 2012: Pluristem's PLX Cells Saves Life Of Child After Bone Marrow Transplantation Failure 73

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76"

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects